Shiseido has signed a binding agreement to sell its Chinese subsidiary, Shiseido Liyuan Cosmetics (SLC), to an investor consortium led by IDG Capital, a private equity firm headquartered in Hong Kong. The transfer covers the whole of the company, which manufactures and sells the Aupres brand in China. Financial terms of the transaction were not disclosed.
The deal is expected to close between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals that include clearance in China.
Shiseido frames the divestment as part of its 2030 Medium-Term Strategy, under which it is seeking to improve profitability and capital efficiency. The group says it intends to concentrate management resources on the areas where it holds what it describes as the greatest competitive advantage, in order to drive sustainable growth and strengthen its competitiveness in China. According to the company, the sale removes a business that would have required continued investment in product innovation and digital capabilities, and allows the group to focus on priority brands and higher-growth opportunities.
Ownership and assets
Under the structure of the transaction, funds managed by IDG Capital will hold 95% of the equity through two special purpose vehicles, while a limited partnership enterprise set up mainly by SLC's incoming management team will hold the remaining 5%. The deal includes SLC's Beijing factory and its production equipment. Shiseido said it believes independent operation under IDG will support SLC's sustainable growth and brand value.
Transition support
To ensure a smooth handover, Shiseido will license the intellectual property rights that IDG needs to run the business. For a specified period after the transfer, it will also provide support on new product development, technical assistance for the stable supply of existing products, and continued supply of raw materials and selected products. Shiseido says the remaining collaboration is intended to maintain the subsidiary's innovation capabilities, product quality and business continuity.
Joint venture history
SLC was set up in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group, which is owned by the Beijing Municipal Government. The company has sold the C-beauty brand Aupres since 1994. With the current joint venture agreement due to expire in December 2026, the parties agreed not to renew it; on September 1, 2026, Shiseido acquired Beijing Liyuan's 35% stake, taking full ownership ahead of the sale.
Profitability backdrop
The divestment follows Shiseido's third-quarter 2026 results, in which core operating profit rose 124.3% to ¥67.5 billion (US$422.13 million). The company attributed the recovery to restructuring, cost reductions and improved margins rather than to strong product demand, with like-for-like sales growing 0.7%. It raised its full-year core operating profit forecast from ¥59 billion (US$433 million) to ¥87 billion (US$546 million).
Shiseido describes China as a strategically important market and an attractive, dynamic one in which the competitive landscape continues to evolve amid rapid e-commerce expansion, changing consumer behaviour and the emergence of diverse market participants.
